Over the 20 years studied, deaths from breast cancer were similar in all groups, with 8.5% of women who had lumpectomies, 9% of women who had mastectomies, and 8.5% of women who had double ...

Groundbreaking new treatment for aggressive breast cancer has 100% survival rate By . Reda Wigle. Published May 30, 2025, 9:18 a.m. ET.

A new era in cancer therapies is at hand New therapeutic strategies build on the success of immunotherapy. Claudia López Lloreda, Undark Magazine – May 12, 2025 9:54 am | 51 ...

In February 2023, I was diagnosed with Stage I breast cancer—and I'm ready to share my story now in a way that I hope is useful. This wasn't my first cancer scare.

Enhertu (fam-trastuzumab deruxtecan-nxki; T-DXd) combined with Perjeta (pertuzumab) as first-line treatment improved progression-free survival (PFS) versus standard care for patients with ...

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer. New England Journal of Medicine , 2025; 392 (3): 249 DOI: 10.1056/NEJMoa2406070 Cite This Page : ...

By October 2019, the treatments had been succcessful, but four years later, in March 2023, the cancer returned—this time a different, more aggressive kind of breast cancer, called Her2+.

My 42-Year-Old Mom Is the Best Dressed in Every Room—These 6 Breezy T-Shirt Dresses Are in Her Cart, From $14. Story by Isabel Bekele • 33m. They’re perfect for the sticky days ahead.

Adverse events in patients treated with neoadjuvant chemo/immunotherapy for triple negative breast cancer: results from seven academic medical centers, Breast Cancer Research and Treatment, (2025 ...

Singer Jessie J has breast cancer. Early breast cancer, mind you, and she’s taking care of it as soon as possible. Miley Cyrus, ahead of the release of her upcoming album ‘Something Beautiful ...

The APHINITY study (Adjuvant Pertuzumab and Herceptin IN Initial TherapY in Breast Cancer) is a global phase 3 trial that enrolled 4,804 people with operable HER2-positive early-stage breast cancer.